Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q35979113)
Watch
English
New sources of drugs for hematologic malignancies
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
3357971
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21511957%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
review article
1 reference
stated in
Europe PubMed Central
title
New sources of drugs for hematologic malignancies
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
3357971
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21511957%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
author
Paul A. Spagnuolo
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
3357971
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21511957%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
Aaron Schimmer
series ordinal
6
1 reference
stated in
Europe PubMed Central
PMC publication ID
3357971
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21511957%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
author name string
Mahadeo A Sukhai
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
3357971
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21511957%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
Scott Weir
series ordinal
3
1 reference
stated in
Europe PubMed Central
PMC publication ID
3357971
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21511957%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
James Kasper
series ordinal
4
1 reference
stated in
Europe PubMed Central
PMC publication ID
3357971
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21511957%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
Lavonne Patton
series ordinal
5
1 reference
stated in
Europe PubMed Central
PMC publication ID
3357971
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21511957%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
language of work or name
English
0 references
publication date
21 April 2011
1 reference
stated in
Europe PubMed Central
PMC publication ID
3357971
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21511957%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
published in
Blood
1 reference
stated in
Europe PubMed Central
PMC publication ID
3357971
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21511957%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
volume
117
1 reference
stated in
Europe PubMed Central
PMC publication ID
3357971
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21511957%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
issue
25
1 reference
stated in
Europe PubMed Central
PMC publication ID
3357971
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21511957%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
page(s)
6747-6755
1 reference
stated in
Europe PubMed Central
PMC publication ID
3357971
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21511957%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
cites work
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
Incentives for drug development--the curious case of colchicine
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
The value of drug repositioning in the current pharmaceutical market
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
New therapies in multiple myeloma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
Thalidomide use in the US : experience with pregnancy testing in the S.T.E.P.S. programme
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
Estimating the cost of new drug development: is it really 802 million dollars?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
The price of innovation: new estimates of drug development costs
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
Thalidomide: current and potential clinical applications
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
The promyelocytic leukemia (PML) protein suppresses cyclin D1 protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
Antitumor activity of thalidomide in refractory multiple myeloma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
2 October 2017
Orphan drugs. BioMarin Europe replies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
27 July 2018
Gefitinib induces myeloid differentiation of acute myeloid leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
27 July 2018
Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
24 September 2018
Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
24 September 2018
Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
24 September 2018
Thalidomide and hematopoietic-cell transplantation for multiple myeloma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
24 September 2018
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
24 September 2018
Thalidomide therapy for low-risk Myelodysplasia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
24 September 2018
The evolution of thalidomide and its IMiD derivatives as anticancer agents
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
24 September 2018
Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
24 September 2018
Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
24 September 2018
Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
24 September 2018
Thalidomide for the treatment of patients with myelodysplastic syndromes
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357971
retrieved
24 September 2018
Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/21511957
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/21511957
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/21511957
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Clinically relevant end points and new drug approvals for myeloma
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/21511957
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1182/BLOOD-2011-02-315283
1 reference
stated in
Europe PubMed Central
PMC publication ID
3357971
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21511957%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
PMC publication ID
3357971
1 reference
stated in
Europe PubMed Central
PMC publication ID
3357971
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21511957%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
PubMed publication ID
21511957
1 reference
stated in
Europe PubMed Central
PMC publication ID
3357971
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21511957%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
ResearchGate publication ID
51069158
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
